KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Cash & Equivalents for 7 consecutive years, with $618.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 33.4% to $618.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $618.7 million through Dec 2025, down 33.4% year-over-year, with the annual reading at $618.7 million for FY2025, 33.4% down from the prior year.
  • Cash & Equivalents hit $618.7 million in Q4 2025 for Royalty Pharma, down from $938.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $2.2 billion in Q2 2023 to a low of $477.0 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $1.3 billion across 5 years, with a median of $1.0 billion in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 898.21% in 2021 and later crashed 72.12% in 2023.
  • Year by year, Cash & Equivalents stood at $1.5 billion in 2021, then increased by 11.01% to $1.7 billion in 2022, then tumbled by 72.12% to $477.0 million in 2023, then surged by 94.76% to $929.0 million in 2024, then tumbled by 33.4% to $618.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for RPRX at $618.7 million in Q4 2025, $938.9 million in Q3 2025, and $631.9 million in Q2 2025.